Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01622348 · ClinicalTrials.gov registry record · Phase 2
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT01622348 is a Phase 2 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT01622348, a Phase 2 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
Interventions
- DRUG IMO-3100 at 0.16 mg/kg
- DRUG Saline for Injection
- DRUG IMO-3100 at 0.32 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01622348
The ClinicalTrials.gov registry entry for NCT01622348 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IMO-3100 at 0.16 mg/kg is the first listed.
NCT01622348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01622348 about?
NCT01622348 is a clinical study titled "Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
What is the current status of trial NCT01622348?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2012-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01622348?
The interventions under investigation include: IMO-3100 at 0.16 mg/kg (DRUG), Saline for Injection (DRUG), IMO-3100 at 0.32 mg/kg (DRUG).
Who is sponsoring clinical trial NCT01622348?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.